BIBLIOS

Tipo
Artigos em Revista

Tipo de Documento
Artigo Completo

Título
Discovery of N-methylpiperazinyl flavones as a novel class of compounds with therapeutic potential against Alzheimer’s disease: synthesis, binding affinity towards amyloid β oligomers (Aβo) and ability to disrupt Aβo-PrP^C interactions

Participantes na publicação
Ana M. Matos (Author)
CQB
Teresa Man (Author)
Imane Idrissi (Author)
Cleide C. Souza (Author)
Emma Mead (Author)
Charlotte Dunbar (Author)
Joanna Wolak (Author)
Maria C. Oliveira (Author)
David Evans (Author)
James Grayson (Author)
Benjamin Partridge (Author)
Claire Garwood (Author)
Ke Ning (Author)
Gary Sharman (Author)
Beining Chen (Author)
Amélia P. Rauter (Author)
Dep. Química e Bioquímica
CQB

Resumo
With no currently available disease-modifying drugs, Alzheimer’s disease is the most common type of dementia affecting over 47 million people worldwide. In light of the most recent discoveries placing the cellular prion protein (PrPC) as a key player in amyloid β oligomer (Aβo)-induced neurodegeneration, we investigated whether the neuroprotective potential of nature-inspired flavonoids against Aβ-promoted toxicity would translate into the ability to disrupt PrPC-Aβo interactions. Hence, we synthesized a small library of flavones and studied their binding affinity towards Aβo by STD-NMR. C-glucosyl flavones exhibited improved binding affinity with morpholine, thiomorpholine or N-methylpiperazine rings attached to the flavone skeleton in ring B para position. Moreover, a N-methylpiperazinyl flavone displayed suitable physicochemical properties and optimal water solubility even without the sugar moiety, and a high interaction with Aβo involving the whole flavone core. Its C-glucosyl derivative, was, however, the best compound to inhibit PrPC-Aβo interactions in a dose-dependent manner, with 41 % of inhibition capacity at 10 μM. The potential of C-glucosyl flavones and their aglycones as protein-protein interaction inhibitors able to tackle PrPC-Aβo interactions is here presented for the first time, and supports this class of compounds as new prototypes for further development in the treatment of Alzheimer’s disease.


Instituição
FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA

Suporte
Pure and Applied Chemistry

Identificadores da Publicação
ISSN - 1365-3075
eISSN - 0033-4545

Editora
Walter de Gruyter GmbH



Identificadores do Documento
URL - http://dx.doi.org/10.1515/pac-2019-0114
DOI - https://doi.org/10.1515/pac-2019-0114

Identificadores de Qualidade
SCIMAGO Q1 (2018) - 1,24 - Chemistry (miscellaneous)

Keywords
Alzheimer’s disease C-Glucosylation Aβo-PrPC interaction disruptors Flavones ICS29

Download